Addyi Cost in Wyoming 2026: Flibanserin Prices, Coverage, and Compounding Options

What Does Addyi Actually Cost in Wyoming in 2026?

The cash-pay price for brand-name Addyi (flibanserin 100 mg, 30 tablets) at Wyoming retail pharmacies sits at approximately $880 per month in 2026. That figure matches Sprout Pharmaceuticals' manufacturer list price, and because no generic flibanserin tablet has received FDA approval for commercial retail sale, there is no generic to undercut it at the pharmacy counter.

Sprout Pharmaceuticals holds the brand and has not faced generic market entry through the standard Hatch-Waxman pathway, partly because flibanserin's REMS (Risk Evaluation and Mitigation Strategy) program creates additional dispensing requirements. The FDA's current REMS for Addyi requires prescribers, pharmacies, and patients to enroll before dispensing can occur, adding an administrative layer that slows generic competition. You can review the FDA's REMS documentation at the Addyi REMS page on accessdata.fda.gov.

For Wyoming residents who pay $880 out-of-pocket monthly, annual drug costs approach $10,560. That is a substantial burden in a state where the median household income was $68 to 002 in 2023, according to the U.S. Census Bureau via the CDC's social determinants data. Two realistic alternatives lower that number: the Sprout savings card and licensed 503A compounding pharmacies, both discussed in detail below.

How the FDA Approved Flibanserin and What the Evidence Shows

Flibanserin received FDA approval on August 18, 2015, for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was the first non-hormonal, centrally acting drug approved for female sexual dysfunction in U.S. history. The approval was based on data from three key Phase III trials, collectively known as the VIOLET, DAISY, and BEGONIA studies.

The BEGONIA trial (N=1,378) is the most frequently cited. Published in the Journal of Sexual Medicine in 2014, BEGONIA demonstrated that flibanserin 100 mg nightly produced a statistically significant increase in the number of satisfying sexual events (SSEs) per month compared with placebo (P<0.001). Women in the flibanserin arm reported a mean increase of 2.5 SSEs per 28-day period versus 1.5 in the placebo group at 24 weeks. The trial also showed a statistically significant reduction in distress scores on the Female Sexual Distress Scale-Revised (FSDS-R) [1]. Responder rates for "much improved" or "very much improved" on the Patient Global Impression of Change reached 36.2% for flibanserin versus 22.0% for placebo [1].

The FDA's full prescribing information for Addyi notes that the drug works as a postsynaptic serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional activity at dopamine D4 receptors. This mechanism differs entirely from sildenafil-type drugs; flibanserin targets central neurotransmitter balance rather than peripheral vascular tone. The FDA prescribing label specifies 100 mg once daily at bedtime as the only approved dose, and co-ingestion of alcohol is contraindicated due to the risk of severe hypotension and syncope.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction, available through endocrine.org, and the International Society for the Study of Women's Sexual Health (ISSWSH) position statements both recognize flibanserin as an appropriate pharmacologic option for premenopausal women with generalized acquired HSDD when psychological and relationship factors have been addressed. The ISSWSH process-of-care algorithm, published in the Mayo Clinic Proceedings, recommends pharmacotherapy only after ruling out contributing medical conditions and medication side effects [2].

Does Wyoming Medicaid Cover Addyi?

Wyoming Medicaid does not cover Addyi as of 2026. The Wyoming Department of Health's Medicaid program uses a preferred drug list (PDL) maintained through its pharmacy benefit administrator, and flibanserin does not appear on that list. Prior authorization pathways exist for some non-PDL drugs, but HSDD pharmacotherapy has not been added as an approvable category under Wyoming's current Medicaid rules.

This coverage gap is not unique to Wyoming. A 2019 analysis published in the Journal of Women's Health found that Medicaid programs in the majority of states excluded Addyi from formulary coverage, citing the drug's clinical effect size, REMS requirements, and acquisition cost as barriers [3]. Wyoming's Medicaid enrollees who need HSDD treatment are therefore largely limited to cash-pay or manufacturer assistance programs.

If Wyoming Medicaid coverage changes during 2026, the Wyoming Department of Health Medicaid pharmacy page will reflect the updated PDL. Patients should confirm coverage status directly with the Wyoming Medicaid pharmacy program before assuming any change applies to their specific plan.

Which Commercial Insurance Plans in Wyoming Cover Addyi?

Commercial insurance coverage for Addyi in Wyoming is inconsistent and plan-specific. Larger employer-sponsored plans administered by national carriers (Aetna, Cigna, UnitedHealthcare, BlueCross BlueShield of Wyoming) may cover flibanserin under a Tier 3 or Tier 4 specialty formulary placement, but prior authorization is almost universally required.

Prior authorization criteria commonly require documentation of all of the following: a diagnosis of HSDD confirmed by a licensed clinician, absence of a co-morbid mood disorder as a primary driver of low desire, evidence that relationship or psychosocial contributors have been assessed, and confirmation that the patient is premenopausal. Some plans additionally require a trial of psychotherapy or a psychiatry consultation before approving pharmacotherapy.

The American College of Obstetricians and Gynecologists (ACOG) published a committee opinion affirming that HSDD is a legitimate medical diagnosis warranting treatment and that barriers to coverage for effective pharmacologic therapies may contribute to health inequity for women [4]. That statement is available through acog.org. Clinicians in Wyoming who submit prior authorization letters can reference the ACOG position as supporting documentation.

Wyoming residents should call the member services number on the back of their insurance card and ask specifically: "Is flibanserin 100 mg (Addyi, NDC 63402-502-30) covered under my current plan, and what prior authorization criteria apply?" Getting the answer in writing via a coverage determination letter before filling the prescription avoids surprise pharmacy denials.

Is Compounded Flibanserin Legal in Wyoming?

Yes. Wyoming-licensed 503A compounding pharmacies may legally prepare compounded flibanserin for individual patients who hold a valid prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to produce patient-specific preparations when a licensed prescriber writes a prescription for an identified patient and the compounding does not involve bulk drug substances on the FDA's 503B prohibited list. Flibanserin bulk substance is not currently on the FDA's prohibited list for 503A compounding [5].

The FDA's 503A compounding framework requires that each compounded preparation be made for a specific patient rather than pre-manufactured in bulk for general distribution. Wyoming's State Board of Pharmacy enforces these federal standards alongside Wyoming Statute Title 33, Chapter 24, which governs pharmacy practice in the state.

Compounded flibanserin is typically formulated as an oral capsule or troche rather than a tablet, and pricing varies by pharmacy. Some telehealth platforms that operate in Wyoming partner with 503A pharmacies and offer compounded flibanserin for as low as $50 to $100 per month, representing a cost reduction of 88 to 94 percent compared with brand-name Addyi at $880 per month.

One critical regulatory note: 503B outsourcing facilities, which can produce drug preparations without patient-specific prescriptions for hospital and clinic distribution, operate under stricter FDA oversight. Compounded flibanserin from a 503B facility would require the bulk substance to appear on the FDA's 503B "bulks list," and flibanserin is not currently on that list [5]. Wyoming patients should confirm their compounding pharmacy holds a 503A license (not solely a 503B license) before proceeding.

Can Wyoming Residents Get Addyi Through Telehealth?

Yes. Telehealth prescribing of flibanserin is legal in Wyoming. Wyoming is a member of the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in compact member states to obtain expedited licensure to practice telemedicine across state lines. Wyoming also enacted telehealth parity legislation requiring that services covered in person be considered for coverage when delivered via synchronous audio-video telehealth.

To prescribe Addyi via telehealth, clinicians must still complete the REMS-required prescriber enrollment through the Addyi REMS portal, confirm the patient is premenopausal and has been assessed for HSDD using a validated tool such as the DSDS (Decreased Sexual Desire Screener), and document the contraindication counseling regarding alcohol and CYP3A4 inhibitors. The FDA's REMS program mandates a specific patient-provider agreement form before the first prescription is written [6].

Telehealth platforms that prescribe and dispense flibanserin in Wyoming typically bundle the prescriber visit, REMS enrollment, and pharmacy fulfillment (either brand or compounded) into one monthly subscription. That model can reduce total monthly cost substantially compared with a separate physician office visit plus brand-name pharmacy fill.

How Does the Sprout Pharmaceuticals Savings Card Work in Wyoming?

Sprout Pharmaceuticals offers a copay savings card for commercially insured patients that caps the patient's out-of-pocket cost at $99 per month (or lower, depending on the current card terms). The savings card is not available to patients enrolled in any federal or state government health program, including Wyoming Medicaid, Medicare, TRICARE, or any other government-funded benefit.

For eligible Wyoming residents, the card works at REMS-certified pharmacies that have registered with the Addyi program. The prescribing clinician or the patient must activate the card through Sprout's patient support line or the Addyi website. Savings are applied at the pharmacy counter as a point-of-sale discount, reducing the patient's copay from the standard Tier 3 or Tier 4 cost-share to a maximum of $99.

The savings card does not reduce the $880 list price for patients who are completely uninsured and cash-paying. In that scenario, the patient pays the full amount unless they use a third-party discount service such as GoodRx, Blink Health, or NeedyMeds, or unless they switch to compounded flibanserin. GoodRx prices for Addyi in Wyoming ZIP codes in early 2025 have ranged from $820 to $875 per month, offering only a marginal reduction from list price.

Sprout also maintains a patient assistance program (PAP) for uninsured or underinsured patients who meet income thresholds. Applications are submitted through Sprout's dedicated support service. Income eligibility criteria and application forms are updated periodically; current details are available by calling 1-844-ADDYI-55.

Flibanserin Safety Profile: What Wyoming Patients Need to Know Before Starting

Flibanserin's most clinically significant risks are hypotension, syncope, and CNS depression, particularly when combined with alcohol or CYP3A4 inhibitors. The FDA-required REMS program exists specifically because of these interaction risks. The full prescribing information lists the following as contraindications: concurrent use of alcohol, use of moderate or strong CYP3A4 inhibitors (including fluconazole, ketoconazole, and many HIV protease inhibitors), and hepatic impairment [6].

A 2016 pharmacokinetic study published in Clinical Pharmacology and Therapeutics confirmed that co-administration of flibanserin with a single dose of alcohol increased the maximum plasma concentration of flibanserin by 1.4-fold and produced hypotension in 4 of 23 subjects [7]. That study is indexed at PubMed. Wyoming prescribers should review this data when counseling patients who drink socially.

Common adverse effects occurring in at least 5% of flibanserin-treated patients in the BEGONIA trial included dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), compared with placebo rates of 2.0%, 2.9%, 3.9%, and 4.2% respectively [1]. Most adverse effects are dose-dependent and occur more frequently with daytime dosing, which is why bedtime administration is specified.

Drug-drug interactions extend beyond alcohol. Oral contraceptives, which many premenopausal women use, are weak CYP3A4 inhibitors and may modestly increase flibanserin plasma levels. The FDA label states that the combination is not absolutely contraindicated but warrants prescriber awareness [6]. A 2020 review in Obstetrics and Gynecology examined flibanserin's interaction profile in the context of common gynecologic prescribing and recommended systematic medication reconciliation before initiation [8].

Patients with hepatic impairment of any degree should not use flibanserin. Liver enzymes should be assessed if there is any clinical suspicion of hepatic disease before prescribing.

How Does Flibanserin Compare to Other HSDD Options Available in Wyoming?

Two FDA-approved pharmacologic treatments for HSDD exist for premenopausal women as of 2026: flibanserin (Addyi) and bremelanotide (Vyleesi). Bremelanotide is a melanocortin receptor agonist administered as a subcutaneous auto-injection approximately 45 minutes before anticipated sexual activity, rather than taken daily. Its list price is approximately $1,000 per single-use injector, and it is not indicated for daily use.

A 2019 head-to-head comparison is not yet available in the published literature, but separate Phase III data allow indirect comparison. The RECONNECT trial for bremelanotide (N=1,247) showed a mean increase of 0.5 SSEs per month over placebo at 24 weeks, with nausea occurring in 40% of patients [9]. The BEGONIA trial for flibanserin showed a mean increase of approximately 1.0 SSEs per month over placebo. Both trials used different baseline SSE frequencies, making direct comparison imprecise.

Testosterone therapy, used off-label for HSDD in premenopausal women, is not FDA-approved for this indication in the United States but is recommended by the International Menopause Society and ISSWSH for postmenopausal women. The Menopause Society (formerly NAMS) notes that evidence in premenopausal women is limited and that off-label testosterone use requires individualized risk-benefit discussion [10].

Non-pharmacologic options supported by evidence include cognitive behavioral therapy (CBT) and mindfulness-based interventions. A 2016 meta-analysis in the Journal of Sexual Medicine (N=681 across 10 trials) found that mindfulness-based sex therapy produced significant improvements in sexual desire and distress scores, with effect sizes comparable to flibanserin in some subscales [11].

A Clinical Decision Framework for Wyoming Prescribers and Patients

Wyoming clinicians evaluating a premenopausal patient for HSDD pharmacotherapy can use the following step-by-step approach to determine which cost pathway makes the most sense before writing the first prescription.

Step 1: Confirm HSDD diagnosis using the DSDS or FSFI-D subscale. HSDD requires low desire plus personal distress and cannot be attributed solely to relationship conflict, a co-morbid psychiatric condition, or a medication side effect. The ISSWSH diagnostic criteria published in the Journal of Sexual Medicine in 2017 provide a current diagnostic standard [12].

Step 2: Review the medication list for CYP3A4 inhibitors and document alcohol use. If either contraindication is present and cannot be resolved, flibanserin is not appropriate regardless of cost.

Step 3: Assess payer status. If the patient is on Wyoming Medicaid, commercial coverage is unavailable, and uninsured cash-pay at $880 per month is not feasible, a 503A compounding pharmacy referral should be considered first.

Step 4: If commercially insured, submit prior authorization with ACOG committee opinion and BEGONIA trial data as supporting literature. If approved, apply the Sprout savings card to reduce out-of-pocket cost to $99 or less per month.

Step 5: Complete REMS prescriber enrollment and document the patient-provider agreement regarding alcohol abstinence and driving risk for the first several weeks of therapy.

Step 6: Reassess at 8 weeks. The FDA label and ISSWSH guidelines both indicate that if no meaningful improvement in SSEs or distress scores has occurred after 8 weeks of consistent nightly dosing, flibanserin should be discontinued [6].

Dosing, Administration, and REMS Compliance for Wyoming Patients

The approved dose is flibanserin 100 mg taken orally once at bedtime. Taking it at bedtime rather than in the morning or afternoon minimizes CNS depression and hypotension risk during waking hours. The drug should be swallowed whole with water and does not require food for absorption, though a high-fat meal may delay peak plasma concentration by approximately 1 hour without reducing total exposure [6].

REMS enrollment steps for Wyoming patients are as follows. The prescriber must complete the online Addyi REMS prescriber certification at the Addyi REMS portal on accessdata.fda.gov. The patient must read and sign the Patient-Prescriber Agreement form. The pharmacy must be REMS-certified for Addyi dispensing, which requires separate pharmacy enrollment. Shipping via mail-order REMS-certified pharmacies is permitted and may be the only practical option for patients in rural Wyoming counties where no local retail pharmacy holds REMS certification.

If a patient misses one or more bedtime doses, she should simply resume the next evening. She should never double-dose to make up a missed night. Skipping one or two doses does not require restarting the 8-week efficacy assessment period.

For patients using telehealth, the prescriber typically handles REMS enrollment on the patient's behalf through a platform-integrated workflow. The patient still signs the Patient-Prescriber Agreement, but the process is completed digitally within the telehealth platform's secure portal rather than on paper.